@meri8181

Usually women suffer the largest loss of bone in the five years after menopause. So, your numbers look darn good.
With your numbers I would be wanting Forteo since it builds stronger more resilient bone.
It isn't as effective after bisphosphonate, so some endocrinologists are using Forteo first, not just with those who have high fracture risk.
Preserving Forteo and Tymlos for the greater risk patients is an economic feasibility determination with what we know in 2024.
A decision to remain on a bisphosphonate for 3 years makes sense. I'd choose risidronate Actonel over alendronate Fosamax because it stays in the bone for a shorter duration allowing for better results from the relay medication you 'll need in three to five years.
Anyway, you might not want to an injection every day either.
You'll be more likely to have an adverse reaction with the higher monthly dose. I hope not, but you can always switch back to weekly Fosamax.